Compounds > goserelin

goserelin and Substance-Withdrawal-Syndrome

goserelin has been researched along with Substance-Withdrawal-Syndrome* in 5 studies

Reviews

2 review(s) available for goserelin and Substance-Withdrawal-Syndrome

ArticleYear
[Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11

    Topics: Antineoplastic Agents, Hormonal; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Luteinizing Hormone; Male; Prostatic Neoplasms; Substance Withdrawal Syndrome; Testosterone; Time Factors

2002
[Adverse reaction of LH-RH agonist and its countermeasure].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl

    Topics: Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Libido; Male; Prostatic Neoplasms; Substance Withdrawal Syndrome

2000

Other Studies

3 other study(ies) available for goserelin and Substance-Withdrawal-Syndrome

ArticleYear
Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    Techniques in urology, 2000, Volume: 6, Issue:3

    Several reports have described the antiandrogen withdrawal syndrome with various nonsteroidal antiandrogen agents. To our knowledge, there have been no reports describing a durable undetectable prostate-specific antigen (PSA) response with discontinuation of the antiandrogen agent bicalutamide (Casodex, Zeneca, Wilmington, DE, U.S.A.). We report a case in which a decline of serum PSA to undetectable levels was achieved with bicalutamide discontinuation.

    Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Goserelin; Humans; Male; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds

2000
Multiple polypoid endometriosis--a rare complication following withdrawal of gonadotrophin releasing hormone (GnRH) agonist for severe endometriosis: a case report.
    The Australian & New Zealand journal of obstetrics & gynaecology, 1996, Volume: 36, Issue:2

    A 30-year old female who initially had typical endometriosis treated according to a standard regimen later developed numerous highly vascular endometrial polyps on the vagina, cervix, ureter, serosal surfaces of the uterus, pouch of Douglas (POD) and other areas of pelvic peritoneum as well as the endometrium 8 months after withdrawal of treatment with Zoladex gonadotrophin releasing hormone (GnRH) agonist used for treatment of this disease. We postulate that these polyps developed as a rebound phenomenon upon withdrawal of Zoladex. We believe this is the first report of this complication following use of GnRH analogue.

    Topics: Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Endometriosis; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Polyps; Substance Withdrawal Syndrome

1996
Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
    Onkologie, 1988, Volume: 11, Issue:6

    Topics: Buserelin; Drug Evaluation; Goserelin; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Substance Withdrawal Syndrome; Testosterone

1988